Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in RSV vaccine development is that a non-live virus vaccine would predispose for enhanced disease similar to that seen with the formalin inactivated RSV (FI-RSV) vaccine. Since a mAb specific to RSV G protein can reduce pulmonary inflammation and eosinophilia seen after RSV infection of FI-RSV vaccinated mice, we hypothesized that RSV G peptides that induce antibodies with similar reactivity may limit enhanced disease after subunit or other non-live RSV vaccines. In support of this hypothesis, we show that FI-RSV vaccinated mice administered RSV G peptide vaccines had a significant reduction in enhanced disease after RSV challenge. These data support the importance of RSV G during infection to RSV disease pathogenesis and suggest that use of appropriately designed G peptide vaccines to reduce the risk of enhanced disease with non-live RSV vaccines merits further study.

+More

pulmonary inflammation inactivated rsv disease pathogenesis g peptide vaccines eosinophilia nonlive virus vaccine rsv vaccine development

Hayat Caidi,Jennifer L Harcourt,Ralph A Tripp,Larry J Anderson,Lia M Haynes,Gertrud U Rey,Congrong Miao,Suvang U Trivedi,.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.. 8 (12),.

Hayat Caidi,Jennifer L Harcourt,Ralph A Tripp,Larry J Anderson,Lia M Haynes,Gertrud U Rey,Congrong Miao,Suvang U Trivedi,"Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice." 8

Hayat Caidi,Jennifer L Harcourt,Ralph A Tripp,Larry J Anderson,Lia M Haynes,Gertrud U Rey,Congrong Miao,Suvang U Trivedi,"Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice."